

**Nebraska Medicaid DUR Board Meeting  
Tuesday October 28th, 2025**

**DUR Board Members in attendance:** Marin Broucek, M.D., Matt Titchener R.P., Charlie Moore, R.P. Excused absence: David Randolph, R. P., Jaci Timmons, M. D.

**Nebraska Medicaid and LTC attendees in attendance:** Lee Stutzman, R.P., Pharmacy Director, Leah Spencer, R.N. Program Specialist, Dianne Garside, R.P., Spencer Moore, R.P.

**Contracted attendees:** Jamie Benson, R.P., Nebraska Total Care; Michael Labadie, R.P., Molina Healthcare, Bernadette Ueda, R.P., United Health Care, Shaleigh Hammons, Account Executive, Prime Therapeutics, Sandy Pranger, R.P., Sr. Director Clinical Account Services Prime Therapeutics

**Public Attendees in attendance:** Suzanne Hansen, Gilead; Jodi Fuehrer, Renewal Health Outreach; Jon Freeland, Novo Nordisk; Randy Roth, Merck; Deb Hartle, Walgreens; Ginger Papesch, Novo Nordisk; Tina Hartman, Arcutis; Shelly Nickerson, Neurocrine; Justin Springfield, Gilead; Sherry Betthauser, Jazz

**I. Opening and Introductions**

Lee Stutzman called the meeting to order at 6:30 PM. The meeting was held at the Best Western Plus Lincoln Inn & Suites in Lincoln, NE. A copy of the open meetings act was available. Stutzman introduced the new Pharmacy Director for Molina Healthcare of Nebraska, Michael Labadie.

**II. Declaration of any Conflict of Interest or changes**

No changes in conflict of interest were declared.

**III. Agenda approval**

The agenda for the meeting was approved as follows: Moore-yes, Broucek-yes, Titchener-yes.

**IV. Review and Approval of Minutes from previous Board meeting Sept 9<sup>th</sup>, 2025**

The meeting minutes were approved as follows: Moore-yes, Broucek-yes, Titchener-yes.

**V. Update on Recommendations from Previous Meeting**

Stutzman announced that the age limit on Naltrexone tablets will be lowered from age 18 to 15 years old.

**VI. Retrospective DUR**

Old Business

Spencer Moore presented SUPPORT Act data. Charlie Moore made a motion to review the SUPPORT Act data with the addition of an aggregated view of all 4 therapeutic classes with concomitant utilization among unique members. Motion passed was approved as follows: Moore-yes, Broucek-yes, Titchener-yes.

Further data on Buprenorphine utilization was presented, showing an increase in the number of prescribers from previous data and noting that the State had sent SUD/buprenorphine education to prescribers in May of 2025.

#### New Business

Spencer Moore presented data on Hepatitis C PDL compliance. No questions or comments from the Board.

### **VII.Prospective DUR**

#### Old Business

Dianne Garside presented the Buprenorphine for Opioid Dependence Treatment PA criteria form for annual review. No changes were recommended. A motion to approve the form as written was made by Marin Broucek and was approved as follows: Moore-yes, Broucek-yes, Titchener-yes.

Dianne Garside presented the Insulin-Like Growth Factor PA criteria form for annual review. No changes were recommended. A motion to approve the form as written was made by Charlie Moore and was approved as follows: Moore-yes, Broucek-yes, Titchener-yes.

New Business – None

### **VIII.Special Requests from the Department - none**

#### **IX.Future Meeting Dates**

January 13<sup>th</sup>, 2026, May 12<sup>th</sup>, 2026, August 18<sup>th</sup>, 2026, October or November meeting to be determined

#### **X.Concerns and Comments from the DUR Board**

Charlie Moore notes continued difficulties with pricing and reimbursement from the managed care organizations.

#### **XI.Concerns and Comments from the DUR Director – none**

#### **XII.Concerns and Comments from the State DHHS Representatives– none**

#### **XIII.Concerns and Comments from the MCO Representatives – none**

#### **XIV.Concerns and Comments from the Public Attendees – none**

#### **XV.Adjournment**

Motion to adjourn the meeting was approved at 7:04 PM. No objections were made from the Board.